| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| ArriVent BioPharma, Inc. | 10%+ Owner | Common Stock | 3,929,117 | $91,823,464 | $23.37 | 10 Dec 2025 | Indirect |
| Enfusion, Inc. | 10%+ Owner | Class A common stock, par value $0.001 per share | 4,975,183 | $79,080,534 | $15.90 | 25 Oct 2021 | Indirect |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| AVBP | ArriVent BioPharma, Inc. | 10 Dec 2025 | 1 | -$12,983,320 | 4 | 10%+ Owner | 03 Feb 2026, 16:05 |
| AVBP | ArriVent Biopharma, Inc. | 30 Jan 2024 | 5 | +$9,999,990 | 4 | 10%+ Owner | 01 Feb 2024, 16:47 |
| AVBP | ArriVent Biopharma, Inc. | 25 Jan 2024 | 0 | $0 | 3 | 10%+ Owner | 25 Jan 2024, 21:01 |
| /report/000090266421004622-hillhouse-investment-management-ltd-2021-10-25 | Enfusion, Inc. | 25 Oct 2021 | 1 | -$10,297,766 | 4 | 10%+ Owner | 27 Oct 2021, 16:20 |
| /report/000090266421004570-hillhouse-investment-management-ltd-2021-10-21 | Enfusion, Inc. | 21 Oct 2021 | 0 | $0 | 3 | 10%+ Owner | 21 Oct 2021, 20:00 |